Dr. Wistuba on Maximizing Outcomes With Limited Tissue in Lung Cancer

Ignacio I. Wistuba, MD
Published: Monday, Oct 10, 2016



Ignacio I. Wistuba, MD, chair, Department of Translational Molecular Pathology, Division of Pathology/Lab Medicine, Anderson Clinical Faculty Chair for Cancer Treatment and Research, The University of Texas MD Anderson Cancer Center, discusses how pathologists maximize outcomes with limited tissue in patients with lung cancer.

Challenges with using tissue-based diagnostic tools are related to the shrinking size of available tissue, Wistuba explains, although this is less invasive for patients.

As a community, pathologists have been questioning how much tissue is truly needed to give the best histological diagnosis possible. For example, Wistuba says rather than administering 5 immunohistochemical tests on a patient, 3 is more effective.


Ignacio I. Wistuba, MD, chair, Department of Translational Molecular Pathology, Division of Pathology/Lab Medicine, Anderson Clinical Faculty Chair for Cancer Treatment and Research, The University of Texas MD Anderson Cancer Center, discusses how pathologists maximize outcomes with limited tissue in patients with lung cancer.

Challenges with using tissue-based diagnostic tools are related to the shrinking size of available tissue, Wistuba explains, although this is less invasive for patients.

As a community, pathologists have been questioning how much tissue is truly needed to give the best histological diagnosis possible. For example, Wistuba says rather than administering 5 immunohistochemical tests on a patient, 3 is more effective.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x